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Аннотация
Актуальность. Диагностика уротелиальной карциномы in situ имеет большое значение, поскольку 
обладает прогностической и терапевтической ценностью. Целью исследования было определить 
роль eZH2 и aRid1a в диагностике карциномы in situ. материал и методы. Ретроспективное пере-
крестное исследование включало 24 образца плоских уротелиальных опухолей, 20 образцов cis и 
10 образцов нормального прилегающего уротелия, взятых при цистоскопической биопсии. Во  всех 
случаях была оценена иммуногистохимическая экспрессия eZH2 и aRid1a. результаты. Все образцы 
нормального уротелия показали высокое ядерное окрашивание на aRid1a и отрицательное ядерное 
окрашивание на eZH2. Высокая экспрессия eZH2 наблюдалась в 80 % образцов cis по сравнению с 
20 % плоских уротелиальных опухолей с атипией (p=0,001), в то время как высокая экспрессия aRid1a 
наблюдалась в 70,8 % плоских уротелиальных опухолей с атипией по сравнению с 25 % образцов cis 
(р=0,001). eZH2 был более точным и специфичным при диагностике карциномы in situ. заключение. 
eZH2 и aRid1a являются перспективными диагностическими маркерами уротелиальной карциномы 
in situ. eZH2 более точен и специфичен, чем aRid1a, в диагностике карциномы in situ по сравнению 
с другими плоскими уротелиальными опухолями.
ключевые слова: дисплазия, карцинома in situ, реактивная атипия, eZh2, aRid1a, иммуногистохимия.
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abstract
background. diagnosis of urothelial carcinoma in situ is of great importance because it has prognostic and 
therapeutic value. We aim to determine the utility of eZH2 and aRid1a as a new tool in the diagnosis of 
carcinoma in situ. material and methods. this retrospective cross-sectional study included twenty-four 
specimens of flat urothelial lesions, twenty specimens of cis, and 10 of normal adjacent urothelium that was 
taken by cystoscopic resection biopsy procedure. immunohistochemical expression of eZH2 and aRid1a. 
were evaluated in all studied cases. Results. all normal urothelium specimens showed high nuclear staining 
for aRid1a and negative nuclear staining for eZH2. High eZH2 expression was observed in 80 % of cis 
specimens compared to 20 % of flat urothelial lesions with atypia (p=0.001 ), while high aRid1a expression 
was observed in 70.8 % of flat urothelial lesions with atypia compared to 25 % of cis specimens (p=0.001). 
eZH2 was more accurate and specific in the diagnosis of carcinoma in situ. conclusion. eZH2 and aRid1a 
are promising diagnostic markers for urothelial cis. eZH2 is more accurate and specific than aRid1a in the 
diagnosis of carcinoma in situ versus other flat urothelial lesions.
Key words: dysplasia, carcinoma in situ, reactive atypia, eZh2, aRid1a, immunohistochemistry.
Introduction
Urothelial carcinoma is a major health problem. 
The incidence of urothelial carcinoma worldwide is 
approximately 4.5 % in males and 1.5 in females [1]. 
In Egypt, It represents the second mostly diagnosed 
cancers in men [2]. Early diagnosis of UC may de-
crease the mortality and morbidity rates [3]. According 
to the latest WHO 2016 committee, flat urothelial le-
sions with atypia were classified as reactive urothelial 
atypia, urothelial proliferation of uncertain malignant 
potential (UPUMP), urothelial dysplasia and urothelial 
carcinoma in situ [4]. UPUMP contains no true papil-
lary projections but undulations are common with a 
thickened urothelium but minimal or no cytological 
atypia. These entities may be seen de novo, and in 
this setting, the clinical relevance is unknown. More 
frequently they are seen in patients who have a his-
tory of prior carcinoma or seen adjacent to papillary 
lesions. It is likely that most represent lateral extension 
(‘‘shoulder lesion’’) of a papillary neoplasm [5]. Reac-
tive urothelial atypia may in some instances lead to 
confusion with dysplasia or cause concern for patients. 
Nucleomegaly is the most prominent finding in reac-
tive urothelial changes, but the cells often have a single 
prominent nucleolus and evenly distributed vesicular 
chromatin. The nuclear borders are smooth. The nuclei 
are frequently round, and nuclear pleomorphism is 
lacking [6]. Architecturally, the cells maintain their 
polarity to the basement membrane although a minimal 
loss of polarity may be evident. The mitotic rate may 
be increased with mitoses present predominantly in the 
basal and intermediate urothelium, but atypical forms 
are not seen. Intraurothelial acute or chronic inflam-
mation is commonly identified [7]. It is important to 
recognize that even intraepithelial lymphocytes, by 
themselves, can result in reactive changes. The cyto-
plasm may become more basophilic or eosinophilic 
with loss of cytoplasmic clearing. Clinical history of 
stones, infection, or frequent instrumentation may be 
present. Reactive urothelium may be denuded with 
only a single residual layer of basal cells remaining; 
the residual cells are not hyperchromatic, not enlarged, 
and do not possess nuclear membrane irregularity 
[8]. Urothelial dysplasia (UD) is defined as the loss 
of polarity with nuclear rounding and crowding and 
cytologic atypia that is not severe enough to diagnose 
CIS. CIS and UD are precursor lesions of invasive 
urothelial carcinoma and their detection, especially 
CIS, is associated with a significant risk of progres-
sion and recurrence [9]. CIS is often multifocal and 
can occur in the upper urinary tracts and in the pro-
static ducts and urethra. CIS exists in two settings; 
isolated (primary) CIS and secondary CIS associated 
with papillary urothelial carcinoma. Isolated CIS was 
rare, accounting for about 10 % of all CIS and 1 % 
to 3 % of bladder neoplasm [10]. Although nuclear 
and architectural features are the primary criteria for 
differentiation between CIS and other flat epithelial 
lesions with atypia, it may be difficult in some patients. 
Expression of markers as EZH2 and ARID1A may be 
helpful [11, 12].
The Enhancer of Zeste Homolog 2 (EZH2) is a 
core subunit of the polycomb repressor complex 2 
(PRC2), which is overexpressed in numerous cancers 
and mutated in several others. Notably, EZH2 acts 
as a critical epigenetic repressor through its role in 
histone methylation, it is also an activator of gene ex-
pression, acting through multiple signaling pathways 
in distinct cancer types. Increasing evidence suggests 
that EZH2 is an oncogene and is central to initiation, 
growth and progression of urological cancers [13]. 
AT-rich interacting rich domain 1(ARID1A) belongs 
to a family of proteins containing a highly conserved, 
approximately 100-amino acid DNA binding domain 
called ARID (AT-rich interacting domain). Although 
the ARID domains in general preferentially bind AT-
rich DNA sequences, the ARID1A domain of mamma-
lian ARID1A exhibits general DNA binding character 
without sequence specificity [14]. The ARID1A gene 
maps to chromosome 1p36.11, a region frequently 
deleted in cancer. Initial clues that ARID1A was a 
tumor suppressor came from expression analyses 
that showed decreased ARID1A expression in 30 % 
of renal cancer and 10 % of breast cancer [15]. A syn-
thetic lethality relationship between other SWI/SNF 
components including ARID1A and EZH2 has been 
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revealed revealed in several tumor entities [16]. We 
evaluate the validity of EZH2 and ARID1A expression 
in distinction between carcinoma in situ and other flat 
urothelial lesions
Material and Methods
This retrospective cross-sectional study was per-
formed after approval by the local ethical Committee 
Zagazig University, Institutional Review Board (IRB) 
for human studies (reference number is ZU-IRB 
#:3986-18-9-2017). This study included 54 patients 
were selected from pathology department archival 
blocks in collaboration with urology department, 
Faculty of Medicine, Zagazig University, Egypt, in the 
period from June 2016 to June 2020. The control group 
included 10 specimens from adjacent normal mucosa. 
Twenty-four patients with flat urothelial lesions with 
atypia (nine specimens of UPUMP, eight specimens of 
reactive atypia and seven specimens of dysplasia) and 
20 specimens of CIS. All specimens were obtained by 
urethrocystoscopy and biopsies. They were classified 
according to 2016 WHO/ ISUP [4].
Immunohistochemical staining
Staining was performed with Dako Autostainer link 
48 (Dako) according to manufacturer’s guide.
Iry antibodies
1 – ARID1A [Rabbit polyclonal antibody (Cat. 
GTX129433) isotype: IgG, 1:100-1000 dilution, Gene 
Tex international corporation].
2 – EZH2 [Rabbit polyclonal antibody, Clone 
144CT2.1.1.5, isotype: IgG, 1:50-100 dilution, US 
Biological life sciences USA] Normal human tes-
ticular tissue was used as positive control for EZH2 
while normal human breast and kidney tissue served 
as positive control for ARID1A. Negative controls 
were obtained by replacing the primary antibodies 
with non-immune serum.
The evaluation of ARID1A immunostaining
Nuclear ARID1A expression was considered posi-
tive. Immunoreactivity was assessed by considering 
the extent and the intensity of nuclear staining in the 
tumor cells. Grades of 0–3 were assigned according to 
the percentage of positive tumor cells (0=0 %; 1<25 %; 
2=25–50 %; 3>51 %) and the intensity of staining in 
tumor (0=absence of staining; 1=weak; 2=intermedi-
ate; 3=strong intensity). The combined score was 
calculated by multiplication of the percentage and the 
intensity grade [17]. Receiver operating characteris-
tic (Roc) curve analysis was used for calculating the 
cutoff point.
The evaluation of EZH2 immunostaining
The EZH2 expression was considered positive in 
nuclear expression only. The extent of nuclear EZH2 
protein staining was graded as follows: 1 (<25 % stain-
ing of tumor cells), 2 (25–50 % staining of tumor cells), 
3 (50–75 % staining of tumor cells), 4 (>75 % staining 
of tumor cells). Moreover, the staining intensity was 
quantified as 0 (indicated no expression), 1 (indicated 
weak expression), 2 (indicated intermediate expres-
sion), 3 (indicated strong expression).
The intensity was multiplied by the extension val-
ues to obtain the final immunostaining score (range 
0–12) [18]. Receiver operating characteristic (Roc) 
curve analysis was used for calculating the cutoff 
point.
Statistical Analysis
Statistical analysis was carried out by using SPSS 
version «20.0» (SPSS Inc.). Fisher's exact and χ2 tests 
were applied for comparisons between the nominal 
variables. Independent student t-test (t) was used to 
compare two groups of normally distributed data 
Mann-Whitney U (MW) was used to compare two 
groups of non-normally distributed data. Sensitivity, 
specificity, accuracy, and positive predictive values 
were calculated. The designations true and false 
were based on the study hypothesis that high EZH2 
is expressed in malignancy and true positivity for 
ARID1A is expected in benign and other flat epithelial 
lesions.
Results
Mean age of the cases was 39.8 ± 1.3, most cases 
were males (79.2 %). According to Roc curve analy-
sis the cutoff point of EZH2 immunoreactivity in all 
studied cases was 4 (Fig. 1). They were reclassified 
into two group; low expression (score<4,) and high 
expression (score≥4 was). However, the cutoff point 
Рис. 1. а) Roc-кривая для оценки eZH2; b) Roc-кривая для 
оценки eZH2
Fig. 1. a) Roc curve for eZH2 cut-off point estimation; b) Roc 
curve for eZH2 cut-off point estimation
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Рис. 2. Микрофото: a) высокая ядерная 
экспрессия aRid1a в нормальном эпи-
телии; b) высокая ядерная экспрессия 
aRid1a в случае upump;
c) высокая ядерная экспрессия aRid1a 
в случае реактивной атипии;
d) низкая экспрессия aRid1a в случае 
cis
Fig. 2. microphoto: a) high aRid1a 
nuclear expression in normal epithelium;
b) high aRid1a nuclear expression in a 
case upump; c) high aRid1a nuclear 
expression in a case reactive atypia; d) 
low aRid1a expression in a case of cis
таблица 1/table 1
сравнение eZh2 и aRid1a между cis и другими плоскими уротелиальными опухолями с атипией
















Normal/Нормальные 10 10 (100.0 %) 0 (0.0 %)
<0.001**
0 (0 %) 10 (100 %)
<0.001**
Плоские эпителиаль-
ные опухоли с атипией/ 
Flat epithelial lesions 
with atypia
24 20(80 %) 4(20 %) 7 (29.2 %) 17 (70.8 %)
• UPUMP1 9 9 (100 %) 0 (0 %) 1 (11.1 %) 8 (88.9 %)
• Реактивная атипия/
• Reactive atypia 8 7 (87.5 %) 1(12.5 %) 2 (25.0 %) 6 (75.0 %)
• Дисплазия/Dysplasia 7 4 (57.1 %) 3 (42.9 %) 4 (57.1 %) 3 (42.9 %)
CIS2 20 4 (20 %) 15 (80 %) 16 (75 %) 5 (25 %)
Примечание: 1 – UPUMP: уротелиальная пролиферация с неопределенным злокачественным потенциалом; 2 – CIS: карцинома in situ;                 
** – различия статистически значимые (p≤0,001).
Note: 1 – UPUMP: urothelial proliferation of uncertain malignant potential, 2 – CIS: Carcinoma in situ, ** – p≤0.001 is highly significant.
of ARID1A immunoreactivity in all studied cases was 
(Fig. 1).
Furthermore, they were reclassified into two 
groups: low expression (score<3) and high expression 
(score≥3). High ARID1A expression was significantly 
low in CIS (25 %) compared to its high expression in 
100 % of normal epithelium and 70.8 % of all flat le-
sions with atypia with a highly statistically significance 
difference between them (p-value=0.0002) (Table 1) 
(Fig. 2).
ARID1A expression level was significantly lower 
in CIS compared to normal, UPUMP and reactive aty-
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pia (0.001, 0.004, 0.02) respectively. However, there 
was no statistically significant difference in ARID1A 
expression levels in differentiating CIS from dysplasia 
(p=0.6) (Table 2) (Fig. 3).
In contrast, Overexpression of EZH2 was higher in 
CIS (80 %) compared to its overexpression in 20 % of 
all flat epithelial lesions with atypia and 0 % of normal 
epithelium, with a highly statistically significant differ-
ence between them (p=0.001) (Table 1) (Fig. 4).
Moreover, EZH2 expression levels were statistically 
increased in CIS compared to normal, UPUMP, reactive 
atypia and dysplasia (0.001, 0.001, 0.01, 0.006) respec-
tively (Table 2) (Fig. 5).
Sensitivity, Specificity, and accuracy of high EZH2 
expression in diagnosis of carcinoma in situ versus 
other flat urothelial lesions were 80 %, 88.24 %, 
85.19 % respectively while sensitivity, specificity, 
and accuracy of low ARID1A expression were 75 %. 
79.41 %, 77.78 % respectively (Table 3).
Discussion
Early detection of CIS would help in reduction of 
bladder cancer incidence, morbidity and mortality. 
The differentiation of CIS from other flat lesions with 
atypia is critical because it has both therapeutic and 
prognostic importance [19, 20] Even after publication 
of the 4th edition of WHO/ISUP classifications, the 
distinction between reactive and dysplastic changes 
has not been resolved, There are still no definite mor-
phological criteria to diagnose CIS, and there is great 
Рис. 3. Прямоугольная диаграмма для уровней иммунореак-
тивности eZH2 в нормальных образцах, плоских эпителиаль-
ных опухолях и cis
Fig. 3. Box plot chart for eZH2 immunoreactivity levels in normal, 
flat epithelial lesions and cis
таблица 2/table 2
Экспрессия eZh2 в aRid1a в cis по сравнению с другими плоскими опухолями



















CIS 6.5 ± 3.1 6 (2–12)
0.001**




1.7 ± 1.1 1 (1–4) 7.1 ± 1.8 6 (4–9)
CIS vs UPUMP2
CIS 6.5 ± 3.1 6 (2–12)
0.001**
3.3 ± 1.7 3 (0.0–6) 0.004*
UPUMP 1.9 ± 1.2 1.5 (1–4) 5.7 ± 2.4 5 (4–9)
CIS vs реактивной 
атипии/ 
CIS vs reactive atypia
CIS 6.5 ± 3.1 6 (2–12)
0.01*




2.0 ± 1.4 1.5 (1–4) 5.3 ± 1.6 5 (4–8)
CIS vs  дисплазии/ 
CIS vs Dysplasia
CIS 6.5 ± 3.1 6 (2–12)
0.006*
3.3 ± 1.7 3 (0.0–6)
0.6Дисплазия/ 
Dysplasia 2.5 ± 1.4 2.5 (1–4) 3.7 ± 2.1 3.5 (1–7)
Примечание: ^ = Тест Манна-Уитни; 1 – CIS: карцинома in situ; 2 – UPUMP: уротелиальная пролиферация с неопределенным 
злокачественным потенциалом; * – различия статистически значимые (p<0,05); ** – различия статистически значимые (p≤0,001).
Note: ^= Mann-Witenny test; 1 – CIS: carcinoma in situ; 2 – UPUMP: urothelial proliferation of uncertain malignant potential; * – p˂0.05 is signifi-
cant, ** – p≤0.001 is highly significant.
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Рис. 4. Микрофото: e) низкая экспрессия 
eZH2 в нормальном эпителии; 
f) низкая экспрессия eZH2 в случае 
upump; g) высокая экспрессия eZH2 в 
случае умеренной дисплазии; h) высо-
кая экспрессия eZH2 в случае cis
Fig. 4. microphoto: e) low eZH2 
expression in normal epithelium; f) low 
eZH2 expression in a case of upump; 
g) high eZH2 expression in acase of 
moderate dysplasia; h) high eZH2 
expression in a case of cis
Рис. 5. Прямоугольная диаграмма для уровней иммунореак-
тивности aRid1a в поражениях плоского эпителия и cis
Fig. 5. Box plot chart for aRid1a immunoreactivity levels in flat 
epithelial lesions and cis
таблица 3/table 3
валидность eZh2 и aRidia в диагностике cis по сравнению с нормальными и плоскими 
поражениями с атипией









EZH2 80.0 % 88.24 % 80.0 % 88.24 % 85.19 %
ARIDIA 75.0 % 79.41 % 68.18 % 84.38 % 77.78 %
inter- and interobserver disagreement [4]. Some forms 
of CIS may be difficult in diagnosis such as clinging 
and pagetoid type. So morphology alone is frequently 
insufficient to differentiate CIS from other flat lesions 
with atypia [21]. There is always a thorough work to 
discover a diagnostic marker of CIS to differentiate 
it from other flat epithelial lesions. Moreover, UP-
UMP has 40 % risk to turn into low grade urothelial 
carcinoma after 5 years [4]. Earlier studies suggested 
the use of CK20, CD44, Ki67, p53, p16 and CK5/6 
immunostains as a diagnostic panel for problematic 
flat lesions with atypia [22], this is a large panel with 
a high cost and the discriminatory performance may 
be unsatisfactory in some cases.
EZH2-immunohistochemistry was used in dis-
tinction between malignant and reactive mesothelial 
cells, with 95.5 % sensitivity providing a promising 
diagnostic marker for malignancy [23]MOC-31, 
CEA, or B72.3. Also, ARID1A was used as a diag-
nostic marker for atypical endometrial hyperplasia to 
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noma tissues compared with normal tissues (p=0.002) 
suggesting that ARID1A may act as a tumor suppressor 
in the development of UC and its downregulation may 
play a role in progression of flat urothelial lesions with 
atypia to carcinoma [21].
In comparing the validity of EZH2 and ARIDIA in 
diagnosis carcinoma in situ among the studied group, 
we found that both high EZH2 and low ARIDA1 
expression can be used as a diagnostic marker to 
correctly identify cases of CIS (sensitivity 80 % and 
75 % respectively). Moreover, high EZH2 is more 
specific and accurate than low ARID1A expression 
in differentiating CIS form normal and other flat 
epithelial lesions of the bladder (specificity 88.24 % 
and accuracy 85.19 %) that will be of great value to 
surgical pathologists as adjuncts to morphology in this 
setting especially in small biopsy specimens and urine 
cytology for accurate diagnosis.
Several therapeutic targets in ARID1A mutated can-
cers are in development, including EZH2 inhibitors. 
EZH2 facilitates epigenetic methylation to modulate 
gene expression. EZH2 inhibition in ARID1A mutated 
tumors acts in a synthetically lethal manner to suppress 
cell growth and promote apoptosis [27], revealing a 
new therapeutic target.
Conclusion
EZH2 and ARID1A expression could be used to 
differentiate CIS from benign and other flat epithelial 
lesions. However, EZH2 is more specific and accurate 
in diagnosis of CIS than ARID1A.
This study has been approved by the Faculty of 
Medicine, Zagazig University, Institutional Review 
Board (IRB) for human studies (reference number 
is ZU-IRB #:3986-18-9-2017) and the patients have 
signed an informed written consent.
differentiate it from benign hyperplasia [24]. These 
findings raised our interest for testing both markers 
in bladder tissue.
There are no previous data about the role of EZH2 
and ARID1A in distinction between carcinoma in situ 
and other flat urothelial lesions. In current study, we 
investigated the use of EZH2 and ARID1A as a diag-
nostic marker of CIS. We reported that expression of 
high EZH2 was observed in (80 %) of cases of CIS 
compared to 20 % of flat epithelial lesions with atypia 
and 0 % of adjacent normal epithelium with a highly 
statistically significant difference between them (p-
value=0.001), suggesting that EZH2 is a diagnostic 
marker for CIS. This observation goes in agreement 
with Warrick et al. (2016) study which found that 
EZH2 expression was common in bladder cancer with 
greatest expression seen in CIS in comparison to nor-
mal urothelium and recommended EZH2 as a specific 
marker of CIS and invasive bladder cancer compared to 
benign urothelium [11]. J.D. Raman et al., (2005) also 
demonstrated that EZH2 protein levels were higher in 
UC compared with benign urothelium [25].
Concerning ARID1A our results revealed that 
ARID1A expression was significantly low in CIS 
cases (either isolated or concomitant), compared to 
its high expression in 100 % of normal epithelium 
and 70.8 % of flat epithelial lesions with atypia with 
a highly statistically significance difference between 
them (p-value=0.0002) suggesting the use of ARID1A 
as a diagnostic marker for CIS. Similarly, T. Aso et al., 
(2015) reported that loss of ARID1A tumor suppres-
sor gene may play an important role in carcinogenesis 
and progression of gastric dysplastic lesions to overt 
carcinoma [26]. This observation goes in agreement 
with Q. Cao et al. (2019) who reported that ARID1A 
expression was significantly downregulated in carci-
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